Pharmacological management of Cronkhite-Canada syndrome

Eric M. Ward, Herbert C. Wolfsen

Research output: Contribution to journalReview articlepeer-review

47 Scopus citations


Cronkhite-Canada syndrome (CCS) is a rare, non-inherited gastrointestinal polyposis syndrome associated with characteristic ectodermal abnormalities. A number of potentially life-threatening complications including malnutrition, gastrointestinal bleeding and infection may occur in affected patients and CCS is fatal in many cases. The optimal therapy for CCS is not known but several treatment options have been described. Nutritional support, antibiotics, corticosteroids, anabolic steroids, histamine-receptor antagonists and surgical treatment have all been used with varying degrees of success. Unfortunately, controlled therapeutic trials have not been possible because of the rarity of the disease. Most recently, a combination regimen using histamine-receptor antagonists, cromolyn sodium, prednisone and suppressive antibiotics has been described. The reported treatment options and rates of success are reviewed.

Original languageEnglish (US)
Pages (from-to)385-389
Number of pages5
JournalExpert Opinion on Pharmacotherapy
Issue number3
StatePublished - Mar 1 2003


  • Corticosteroid
  • Cromolyn sodium
  • Cronkhite-Canada syndrome
  • Endoscopic therapy
  • Gastrointestinal polyposis syndromes
  • Idiopathic thrombocytopenic purpura
  • Proton pump inhibitors

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Pharmacological management of Cronkhite-Canada syndrome'. Together they form a unique fingerprint.

Cite this